Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis
NORWOOD, MA -- (Marketwired) -- 10/15/15 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic …